Diagnosis Treatment & Control MCQ Quiz | Leprosy

Welcome to this specialized quiz on the Diagnosis, Treatment, and Control of Leprosy, designed for MBBS students. This module will test your understanding of crucial clinical and public health aspects of managing Hansen’s disease. You will face 25 multiple-choice questions covering key topics such as the cardinal signs for diagnosis, the nuances of Slit-Skin Smear interpretation, the WHO’s Multi-Drug Therapy (MDT) regimens for both paucibacillary and multibacillary cases, and the management of lepra reactions. Furthermore, this quiz delves into the strategies employed under the National Leprosy Eradication Programme (NLEP). After submitting your answers, you can review your score and download a PDF of all questions with the correct answers for your revision. Good luck!

1. What is the minimum duration of Multi-Drug Therapy (MDT) for a new case of Paucibacillary (PB) leprosy in an adult?

2. Which of the following drugs in the MDT regimen for Multibacillary (MB) leprosy has a bactericidal effect and is administered monthly under supervision?

3. A positive Slit-Skin Smear (SSS) showing acid-fast bacilli is a definitive sign for classifying a patient as:

4. The drug of choice for managing severe Type 2 lepra reaction (Erythema Nodosum Leprosum – ENL) is:

5. According to WHO, a paucibacillary (PB) case of leprosy is defined as a patient having:

6. Which of the following is NOT a cardinal sign for the diagnosis of leprosy?

7. The Morphological Index (MI) in a slit-skin smear indicates:

8. Under the National Leprosy Eradication Programme (NLEP), what is the recommended chemoprophylaxis for eligible contacts of a newly diagnosed leprosy patient?

9. Type 1 Lepra Reaction (Reversal Reaction) is a cell-mediated hypersensitivity reaction most commonly seen in which part of the Ridley-Jopling spectrum?

10. A major adverse effect of Clofazimine, used in MDT, is:

11. A patient on MDT for MB leprosy presents with acute pain, swelling, and tenderness over the ulnar nerve, with a sudden loss of sensation in the little finger. This is most likely:

12. The term “Released From Treatment (RFT)” is used when a leprosy patient:

13. Which peripheral nerve is most commonly affected in leprosy, leading to a claw hand deformity?

14. The standard treatment for severe neuritis in a Type 1 Reaction is:

15. What does a Bacteriological Index (BI) of 4+ on a slit-skin smear signify?

16. The primary goal of Disability Prevention and Medical Rehabilitation (DPMR) in leprosy control is to:

17. Which component of the adult MB-MDT blister pack is taken daily without supervision?

18. A “silent neuropathy” in leprosy is characterized by:

19. The WHO Grade 2 disability in leprosy is defined as:

20. What is the main reason for using a combination of drugs (MDT) to treat leprosy?

21. Leprosy is considered “eliminated” as a public health problem when the prevalence rate falls below:

22. The most important action to take when a patient develops a lepra reaction with nerve function impairment is:

23. Foot drop in a leprosy patient is caused by damage to which nerve?

24. What is Lucio’s phenomenon?

25. A patient is declared a “defaulter” under NLEP if they have missed their MDT for:

Author

  • G S Sachin Author Pharmacy Freak
    : Author

    G S Sachin is a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. He holds a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research and creates clear, accurate educational content on pharmacology, drug mechanisms of action, pharmacist learning, and GPAT exam preparation.

    Mail- Sachin@pharmacyfreak.com

PRO
Ad-Free Access
$3.99 / month
  • ✓ No Interruptions
  • ✓ Faster Page Loads
  • ✓ Support Content Creators
Subscribe Now